TY - JOUR
T1 - Sustained and targeted delivery of hydrophilic drug compounds
T2 - A review of existing and novel technologies from bench to bedside
AU - Hawthorne, Daniel
AU - Pannala, Ananth
AU - Sandeman, Susan
AU - Lloyd, Andrew
PY - 2022/11/4
Y1 - 2022/11/4
N2 - The sustained and/or targeted delivery of hydrophilic drugs is an important field within drug delivery, presenting unique challenges when compared to that of hydrophobic drugs. Yet relatively few comprehensive reviews specific to hydrophilic drug delivery have been published recently. In this review, therefore, we seek to establish the recent trends in the delivery of hydrophilic drugs in particular, and recent developments including electrospun core-shell nanofibrous materials, stimuli-responsive hydrogel carriers, amphiphilic drug-drug conjugates (ADDCs), and nanomaterials including polymer nanoparticles (PNPs), solid lipid nanoparticles (SLNs), micelles, liposomes, and mesoporous silica nanoparticles (MSNs). A recurring trend in the field has been the relatively slow translation of novel technologies into viable pharmaceutical products, with few reaching clinical trial phase. Furthermore, we consider the bench-to-bedside potential of these novel technologies, taking into account the capabilities of these concepts to overcome the technical, legislative, and commercial requirements that must be met in order for a viable device to be adopted in the real world.
AB - The sustained and/or targeted delivery of hydrophilic drugs is an important field within drug delivery, presenting unique challenges when compared to that of hydrophobic drugs. Yet relatively few comprehensive reviews specific to hydrophilic drug delivery have been published recently. In this review, therefore, we seek to establish the recent trends in the delivery of hydrophilic drugs in particular, and recent developments including electrospun core-shell nanofibrous materials, stimuli-responsive hydrogel carriers, amphiphilic drug-drug conjugates (ADDCs), and nanomaterials including polymer nanoparticles (PNPs), solid lipid nanoparticles (SLNs), micelles, liposomes, and mesoporous silica nanoparticles (MSNs). A recurring trend in the field has been the relatively slow translation of novel technologies into viable pharmaceutical products, with few reaching clinical trial phase. Furthermore, we consider the bench-to-bedside potential of these novel technologies, taking into account the capabilities of these concepts to overcome the technical, legislative, and commercial requirements that must be met in order for a viable device to be adopted in the real world.
UR - http://www.scopus.com/inward/record.url?scp=85141614358&partnerID=8YFLogxK
U2 - 10.1016/j.jddst.2022.103936
DO - 10.1016/j.jddst.2022.103936
M3 - Article
SN - 1773-2247
VL - 78
JO - Journal of Drug Delivery Science and Technology
JF - Journal of Drug Delivery Science and Technology
M1 - 103936
ER -